GLP Watchdog

Hers vs Push Health

Hers has an open FDA warning letter dated September 9, 2025. Push Health has none. Push Health publishes no GLP-1 price we could capture. Hers starts at $199 a month for compounded semaglutide injection.

To see where both sit among the other sellers, read our best weight-loss injection providers board.

By Ruth Calder · Enforcement Editor
Editorially reviewed. Not medical advice · How we verify contentLast reviewed

The record

Hers / Push Health

Hers logo

Hers

6.8/10

Push Health logo

Push Health

4.1/10

FDA warning letters
None on record
Pharmacy
None named in our record
Lowest standing price
$199/moCompounded semaglutide injection
No GLP-1 price published
States
All 50 states
No state list published
Checked
Prices captured Record checked September 2026
Prices captured Record checked September 2026
Visit Hers
Visit Push Health

Neither Hers nor Push Health pays us. Links to them earn nothing. Scores: Hers 6.8, Push Health 4.1. How we are paid

What the record shows

  1. 01

    Hers has an open FDA warning letter dated September 9, 2025. Push Health has none.

  2. 02

    Hers names three pharmacies. Push Health names no compounding pharmacy in our record.

  3. 03

    Push Health publishes no GLP-1 price we could capture. Hers starts at $199 a month for compounded semaglutide injection.

  4. 04

    Only Hers lists a price for compounded semaglutide injection and brand-name tirzepatide pen.

  5. 05

    Hers lists all 50 states. Push Health publishes no state list.

Prices and terms, product by product

A price is set against the other side only for the same product, and only when both are standing monthly or 4-week rates. Those pairs are compared by yearly cost.

Hers

Push Health

Compounded semaglutide injection

$199/mo

$2,388 a year

Not sold or not priced
Brand-name tirzepatide pen

$299/mo

medication only, membership extra; not compared

Not sold or not priced
Price includes
Medication
Not stated
Billed separately
Clinician visits, coaching
Not stated
Cancel any time
Yes, stated
Yes, stated
Minimum term
None
None
Refunds
No refund guaranteed once the pharmacy has processed an order
Full refund if you cancel before the provider writes a prescription; none after

Read off each seller’s own pages. Hers: September 28, 2026. Push Health: September 28, 2026. Every plan and dose we hold is on the full review.

The case for each

The case for Hers

6.8/10
  • Sells compounded semaglutide injection and brand-name tirzepatide pen, which Push Health does not price
  • Open FDA warning letter, September 9, 2025
  • Price leaves out clinician visits and coaching
Visit Hers

The case for Push Health

4.1/10
  • No FDA warning letter on record
  • Names no compounding pharmacy
  • Publishes no state list
  • Publishes no GLP-1 price
Visit Push Health

Scores

Hers 6.8 · Push Health 4.1 out of 10. Six weighted parts.

Value25%

3.0A
vs
B
3.0

Effectiveness25%

10.0A
vs
B
5.0

User Experience15%

8.0A
vs
B
3.0

Trust & Safety15%

7.0A
vs
B
4.0

Accessibility10%

10.0A
vs
B
5.0

Support10%

3.0A
vs
B
5.0

The score is the same formula for every seller. Payment does not enter it. Method

Hers vs Push Health: questions

Hers has an open FDA warning letter dated September 9, 2025. Push Health has none. Letters are matched to a seller by company, domain and address, never by a similar name.
Hers names three pharmacies. Push Health names no compounding pharmacy in our record.
Hers states you can cancel at any time; refunds: no refund guaranteed once the pharmacy has processed an order. Push Health states you can cancel at any time; refunds: full refund if you cancel before the provider writes a prescription; none after.
Neither Hers nor Push Health pays us. Links to them earn nothing. Scores: Hers 6.8, Push Health 4.1.

Other sellers we are paid by

Affiliate partners outside this pair. Each has its own record and review, scored the same way.

Sellers closest to these two

Matched on molecule, form and price. Every pair we list · The register

Brand names on this page are registered marks. Novo Nordisk holds Wegovy®, Ozempic® and Rybelsus®; Eli Lilly holds Zepbound®, Mounjaro® and Foundayo®. Neither company has any tie to GLP Watchdog. Trademarks